Search the Newsreel

Nvwm LLC Buys 1,079 Shares of GE Vernova Inc. $GEV

Nvwm LLC increased its stake in GE Vernova Inc. by 23.2% in the second quarter, purchasing 1,079 additional shares, bringing its total to 5,735 shares valued at $6.74 million. GE Vernova reported strong revenue growth but missed EPS estimates, while analysts maintain a "Moderate …

Price to sales forward of RiverNorth Managed Duration Municipal Income Fund, Inc. – NYSE:RMM

This article displays the "Price to sales forward" metric for RiverNorth Managed Duration Municipal Income Fund, Inc. (NYSE: RMM). It provides financial data within the TradingView platform context, indicating the period and value of this financial ratio. The content is primarily a data point …

Price to earnings forward of RiverNorth Managed Duration Municipal Income Fund, Inc. – NYSE:RMM

The article focuses on the "Enterprise value to revenue forward" metric for RiverNorth Managed Duration Municipal Income Fund, Inc. (NYSE: RMM). It presents a snippet of financial data for this specific metric, indicating a period, value, and change percentages. The content is primarily a …

Enterprise value to revenue forward of RiverNorth Managed Duration Municipal Income Fund, Inc. – NYSE:RMM

The article focuses on the "Enterprise value to revenue forward" metric for RiverNorth Managed Duration Municipal Income Fund, Inc. (NYSE: RMM). It presents a snippet of financial data for this specific metric, indicating a period, value, and change percentages. The content is primarily a …

How Ge Vernova Inc. When-issued (GEV) Affects Rotational Strategy Timing

This article analyzes Ge Vernova Inc. (GEV) using AI models, indicating a strong overweight bias across all time horizons due to strong sentiment and a mid-channel oscillation pattern. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss …

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

Kestra Private Wealth Services LLC Acquires 2,804 Shares of GE Vernova Inc. $GEV

Kestra Private Wealth Services LLC increased its stake in GE Vernova Inc. (NYSE:GEV) by 15.7% during the second quarter, acquiring an additional 2,804 shares to hold a total of 20,631 shares valued at approximately $24.2 million. The article highlights GE Vernova's strong demand for …

Cadinha & Co. LLC Has $27.30 Million Stock Position in GE Vernova Inc. $GEV

Cadinha & Co. LLC significantly increased its stake in GE Vernova Inc. (NYSE:GEV) by 180.0% in the second quarter, holding 23,236 shares valued at $27.30 million, making it their 6th largest position. Several other institutional investors also adjusted their holdings in GEV, while CEO …

Should Investors Take Profits in GE Vernova After Its Big Run?

GE Vernova stock has surged 674% since its spinoff, driven by massive demand for its power equipment from AI data centers, leading to a $176 billion backlog. While its valuation is high, reflecting strong growth prospects, early investors might consider taking some profits to …

Why GE Vernova (GEV) Is Emerging as an AI Power Winner

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index's …

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Kyverna Therapeutics (NASDAQ:KYTX) to a loss of $0.66 per share, an improvement from its previous forecast of a $0.78 loss. The firm maintained a "Buy" rating and a $25.00 price target for the stock. …

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake

Bain Capital Life Sciences Opportunities III, LP has reported a 4.75% ownership stake in Kyverna Therapeutics, Inc. (KYTX) through a Schedule 13G/A SEC filing. The fund holds 2,885,000 shares of common stock, representing a passive investment based on the company's 60,795,212 outstanding shares as …

Could AI Infrastructure Fuel GE Vernova’s (GEV) Next Rally?

Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts

Kyverna Therapeutics (NASDAQ:KYTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $30.00, significantly above its current price of $8.08. Insider ownership has increased, with hedge funds and institutions owning 18.08% of the stock. The company recently …

Ascentis Wealth Management LLC Raises Holdings in GE Vernova Inc. $GEV

Ascentis Wealth Management LLC significantly increased its stake in GE Vernova Inc. by 60,776.3% in the second quarter, now owning 138,798 shares valued at over $163 million. The article also highlights key news impacting GE Vernova, including strong Q2 revenue growth, AI and data-center …

GE Vernova (GEV) After Strong Q2 Results And Raised Guidance Looks Fully Valued

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. GE Vernova (GEV) is back in focus after its strong second quarter 2026 report, where the company highlighted higher orders, revenue growth, improved margins and raised guidance …

GE Vernova (GEV) Stock Could Be 14% Overvalued As Backlog Hits Record High

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. GE Vernova stock has surged over the past year, yet its valuation signals are split, with the Discounted Cash Flow (DCF) intrinsic value suggesting …

Kyverna Therapeutics advances autoimmune drug mivocabtagene autoleucel with strong trial results and regulatory progress.

Kyverna Therapeutics is making significant progress with its autoimmune drug, mivocabtagene autoleucel, showing strong trial results where all 26 patients stopped chronic immunotherapies and most reported improved mobility. The company is pursuing a rolling Biologics License Application, aiming for completion by late 2026 and …

Can GE Vernova's Strong Q2 Results Fuel Further Earnings Growth?

GE Vernova Inc.'s GEV second-quarter 2026 results suggest that the company is entering a stronger earnings growth phase. The company delivered significant growth in orders and revenues, expanded margins and generated substantial free cash flow during the quarter. With demand continuing to build across …

2,297 Shares in GE Vernova Inc. $GEV Bought by Processus Wealth & Capital Management LLC

Processus Wealth & Capital Management LLC acquired 2,297 shares of GE Vernova Inc. (NYSE:GEV) in the second quarter, valued at approximately $2.7 million. Several other institutional investors also adjusted their stakes in the company, which reported a 21.9% year-over-year revenue increase to $11.1 billion …

SAB Events & Governance Now Media reports standalone net loss of Rs 0.19 crore in the June 2026 quarter

Five water companies to further increase bills with biggest rise for Southern Water

Five water companies are to further increase bills as part of a new £3.4bn infrastructure investment. The greatest annual bill rise is faced by customers of Southern Water - which covers Hampshire, the Isle of Wight, Sussex and Kent - where there is a …

Blue Energy, GE Vernova Hitachi Sign Agreement to Launch Next Phase of Texas Gas-Plus-Nuclear Project

Blue Energy, GE Vernova Hitachi Nuclear Energy (GVH) have signed an agreement to advance a 2.5 GW gas-plus-nuclear power plant project in Victoria, Texas. This collaboration aims to meet surging U.S. electricity demand by combining GE Vernova 7HA.02 gas turbines and GVH BWRX-300 SMRs, …

(RMMZ) Movement as an Input in Quant Signal Sets

This article provides an AI-generated analysis of Rivernorth Managed Duration Municipal Income Fund Ii Inc. (NASDAQ: RMMZ), indicating a neutral sentiment with resistance being tested. It outlines three institutional trading strategies: a position trading strategy (long), a momentum breakout strategy, and a risk hedging …

Trading the Move, Not the Narrative: (RMM) Edition

This article analyzes Rivernorth Managed Duration Municipal Income Fund Inc. (NYSE: RMM), highlighting strong near-term sentiment that could shift to neutrality mid-term and a positive long-term bias. It details an exceptional 11.5:1 risk-reward short setup and provides institutional trading strategies for long, breakout, and …

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX

Kyverna Therapeutics (KYTX) announced its Q2 2026 earnings on August 12, 2026, reporting an EPS of -$0.63, beating the consensus estimate by $0.05. The company's earnings are projected to improve from ($2.70) to ($2.62) per share in the upcoming year. The article details Kyverna …

Tema ETFs LLC Increases Position in GE Vernova Inc. $GEV

Tema ETFs LLC significantly increased its holdings in GE Vernova Inc. by 37.9% in the second quarter, making it their 14th largest position. Other institutional investors like Auto Owners Insurance Co, Norges Bank, and Northwestern Mutual Wealth Management Co. also substantially boosted their stakes. …

G&S Capital LLC Acquires New Position in GE Vernova Inc. $GEV

G&S Capital LLC has acquired a new position in GE Vernova Inc. (NYSE:GEV) during the second quarter, purchasing 3,038 shares valued at approximately $3.57 million. Several other investment firms also increased their holdings in the company. Analysts maintain a "Moderate Buy" rating with a …

3 Big Reasons to Love GE Vernova (GEV)

3 Big Reasons to Love GE Vernova (GEV) GE Vernova's 25.3% return over the past six months has outpaced the S&P 500 by 14.2%, and its stock price has climbed to $990.50 per share. This performance may have investors wondering how to approach the …

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS

Kyverna Therapeutics (NASDAQ:KYTX) reported a Q2 loss of $0.63 per share, which beat analyst expectations by $0.04. Following the announcement, shares rose 1.6% to $8.02. The company currently holds a "Moderate Buy" consensus rating from analysts with a target price of $30.00.

Kyverna Therapeutics Q2 Results: EPS beats estimate, losses narrow 35%

Kyverna Therapeutics reported a Q2 2026 net loss per share of $(0.63), surpassing analyst expectations and narrowing its year-over-year loss by 35%. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) and is on …

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Kyverna Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement indicating the availability of these financial results. Readers can access the full report via TradingView, which provides content from Reuters and other …

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows